EPIX
ESSA Pharma Inc.0.2012
+0.0000+0%
Oct 8, 4:00:01 PM EDT
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
9.52MP/E (TTM)
-Basic EPS (TTM)
-0.57Dividend Yield
0%Recent Filings
8-K
ESSA advances acquisition timeline
ESSA Pharma secured an amended Interim Order from the Supreme Court of British Columbia on September 25, 2025, greenlighting its special meeting on October 3 to vote on the acquisition by non-profit XenoTherapeutics. The order sets dissent notices due October 1 and final court approval hearing for October 7. Timeline advances the deal. Yet risks like litigation and disruptions loom large.
8-K
ESSA adjourns meeting for deal talks
ESSA Pharma adjourned its special meeting from September 10 to September 29, 2025, to negotiate possible revisions to the financial terms of its acquisition by non-profit XenoTherapeutics, focusing on cash forecasts and upfront distributions to shareholders. This delay, while extending uncertainty, allows for potential improvements in deal value amid ongoing discussions. The court approval hearing is also postponed. Risks include litigation and business disruptions from the transaction.
8-K
ESSA corrects distribution trading details
ESSA Pharma clarified a prior press release error on August 25, 2025, correcting the due bill trading period for its US$80,000,000 cash distribution to August 19 through August 22, 2025. The distribution, paid on August 22 at approximately US$1.6910318 per common share, supports the company's winding-up amid its pending acquisition by XenoTherapeutics. Shares traded ex-dividend starting August 25. This resolves confusion but underscores transaction risks like delays.
8-K
Ex-dividend date set
ESSA Pharma announced Nasdaq's ex-dividend date of August 25, 2025, for its $80 million return of capital distribution, payable August 22 at $1.69 per share, tied to the pending acquisition by non-profit XenoTherapeutics. Shares will trade with due bills from August 19 to 25, transferring distribution rights to buyers while sellers forfeit them. This setup ensures fair trading amid the wind-up. Risks include potential delays in approvals.
10-Q
Q3 FY2025 results
ESSA Pharma's Q3 FY2025 results reflect a sharp pivot after terminating its masofaniten clinical trials in October 2024, slashing R&D expenses to a $0.5M recovery from $5.5M a year earlier, while general and administrative costs climbed to $5.4M from $3.2M, yielding a narrower net loss of $4.0M versus $7.2M in Q3 FY2024 (derived). For the nine months ended June 30, 2025, the net loss eased to $18.9M from $22.2M year-over-year, driven by reduced R&D outlays to $8.4M from $17.0M, though share-based compensation added $3.2M to expenses. Cash and equivalents stood at $86.0M with $23.7M in short-term investments, down from $103.7M at fiscal year-end, supporting a runway amid the wind-down; operating cash burn totaled $17.5M for the period. No debt burdens the balance sheet. Post-quarter, ESSA inked a deal for XenoTherapeutics to acquire it via cash and CVRs, eyeing closure in H2 2025. Yet regulatory hurdles could snag approvals.
ATOS
Atossa Therapeutics, Inc.
0.72+0.01
BCAX
Bicara Therapeutics Inc.
18.15-0.21
BIOE
Bio Essence Corp.
0.05+0.00
ELVN
Enliven Therapeutics, Inc.
16.91-0.26
ESSI
Eco Science Solutions, Inc.
0.01+0.00
LSTA
Lisata Therapeutics, Inc.
2.05+0.01
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
ONCO
Onconetix, Inc.
1.94-0.04
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07
TTNP
Titan Pharmaceuticals, Inc.
4.61-0.18